ESALF News and Press, Eisai Co Ltd From 02/06/23

The following slide deck was published by Eisai Co., Ltd. in conjunction with their 2022 Q3 earnings call. For further details see: Eisai Co., Ltd. 2022 Q3 - Results - Earnings Call Presentation

Summary Biogen's business focuses on developing and commercializing drugs aimed at treating patients living with neurological and neurodegenerative diseases. The company's total revenue was $2,508.5 million in the third quarter of 2022, down 9.7% from the previous year. The decline ...

Summary Anavex 2-73/blarcamesine at high concentrations in early Alzheimer's disease leads to improvements in cognition and activities of daily living that are largely sustained for 148 weeks in most individuals. Alzheon's ALZ-801 reduces cognitive decline in ApoE4 carriers by about the...

Eisai ( OTCPK:ESALY )( OTCPK:ESALF ) has submitted a marketing authorization application to regulators in Japan for the Alzheimer's disease treatment lecanemab. The application is supported by results from the phase III Clarity AD study and a phase IIb study, both of which showed leca...

NOTE: This story will be updated throughout the day as additional information becomes available. The US FDA on Friday approved Biogen ( NASDAQ: BIIB ) and Eisai's ( OTCPK:ESALY ) Alzheimer's therapy lecanemab, which will be marketed as Leqembi. The approval of Leqe...

Summary Lecanemab only significantly slows down the progression of Alzheimer's disease in APOE4 carriers. Lecanemab is suspected of causing at least three deaths. The FDA may still grant approval to lecanemab with a warning label regarding brain bleeds and brain swelling. Medica...

A third patient has died while taking Biogen ( NASDAQ: BIIB ) and Eisai's ( OTCPK:ESALY ) ( OTCPK:ESALF ) experimental Alzheimer's treatment lecanemab and the fatality is being linked to the drug, Science reported. The journal said the death was in a 79-year-old woman ...

Summary Anavex's 2-73/blarcamesine produced significant reductions in cognitive decline in early Alzheimer's disease as measured by ADAS-Cog and CDR-SB scores. Those who had improvements in cognition did so by an average ADAS-Cog score of 4 points, which is considered to be clinically s...

Eisai Co., Ltd. (ESALF) Q2 2022 Earnings Conference Call November 7, 2022 02:00 ET Company Participants Haruo Naito - Representative Corporate Officer and Chief Executive Officer Ivan Cheung - Senior Vice President, Global Alzheimer's Disease Officer, President, Amer...

Call Start: 02:00 Call End: 03:28 Eisai Co., Ltd. (ESALF) Q2 2023 Earnings Conference Call November 7, 2022 02:00 ET Company Participants Haruo Naito - Representative Corporate Officer and Chief Executive Officer Ivan Cheung - Senior Vice President, Global Al...